Patients Emerging from the shadow of COVID-19 We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos.
Patients Deep Dive: Patients and Partnerships As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.